ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue54,51552,22245,658
Cost of Revenue27,46628,81719,458
Gross Profit27,04923,40526,200
Operating Expenses
Research Development13,14721,12719,731
Selling General and Administrative30,35326,39526,931
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-16,451-24,117-20,462
Income from Continuing Operations
Total Other Income/Expenses Net1,131-122-22
Earnings Before Interest and Taxes-15,320-24,239-20,484
Interest Expense1,4231,4231,423
Income Before Tax-16,743-24,239-20,484
Income Tax Expense-100175
Minority Interest---
Net Income From Continuing Ops-16,743-24,339-20,659
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-16,743-24,339-20,659
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-16,743-24,339-20,659